Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q2 2022 call → NOThe question asks whether management lays out a timetable of specific conversions - identified pieces of business that are already secured or in motion, each attached to an approximate time frame, so the forward story reads as a schedule of things turning on rather than hopes about demand. Looking at the transcript, management discusses: - The CDMO business and its challenges - retooling, integration, longer lead times - The DSA segment with strong backlog - The RMS segment - The manufacturing segment Key forward-looking statements: - "We are very pleased to report that our Memphis site was recently audited and approved by European regulatory authorities or the EMA to commercially manufacture cell therapies. This is a significant accomplishment that prepares us to undertake future commercial projects." - "We are encouraged that these developments will help improve the performance of the CDMO business next year." - "we believe that CDMO growth opportunity remains robust" - "we have implemented a refined vision and a strategy for our combined CDMO business, which includes developing centers of excellence for plasmids at our Cognate UK operations for viral vectors at Vigene in Rockville, Maryland, and for gene modified cell therapy production in Memphis, Tennessee." But these are described as future developments, not secured business with specific timetables. The Memphis EMA approval is a capability, not a secured contract with timing. For the DSA segment: "we continue to expect that the growth rate will approach 20% in the second half, tracking to our initial plan" - this is based on backlog and demand, but the backlog is existing business. However, the question asks about specific conversions - identified pieces of business already secured with timing. The CDMO business: "we are retooling the production suites and retraining staff to return the capacity to its original purpose, producing plasmids, which is taking longer than expected" - this is a delay explanation, not a schedule of secured conversions. The forward story seems to rest on demand strength, backlog, and general optimism about the CDMO business improving "next year" without specific secured contracts with timetables. The Memphis EMA approval is a capability milestone, not a secured contract. The centers of excellence are being developed but no specific secured business with timing is mentioned.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.